|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
08037 CH BIOTECH SER
Nominal 
0.610 -0.005 (-0.813%) | 2026/06 - Interim HKD(K$) | %Chg (Compare to Interim) | 2025/12 HKD(K$) | 2024/12 HKD(K$) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | |
| Turnover | 37,226 | -4.234% | 73,503 | 70,509 | 211,985 | 1,851,532 |
| Cost of Sales | (32,037) | -11.817% | (65,777) | (75,449) | (177,661) | (750,575) |
| Gross Profit | 5,189 | 104.131% | 7,726 | (4,940) | 34,324 | 1,100,957 |
| 2026/06 - Interim HKD(K$) | %Chg (Compare to Interim) | 2025/12 HKD(K$) | 2024/12 HKD(K$) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | (52,713) | (16,186) | -- | |
| Change in FV & Impairment on Others | 84,233 | -- | (9,864) | (40,798) | 9,795 | 19,091 | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | (2) | 1,696 | |
| Other Non-operating Items | -- | -- | -- | -- | (26) | (3,707) | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | (7,678) | (4,180) | |
| Profit / (Loss) before Taxation | 26,146 | -- | (81,697) | (252,797) | (142,025) | 862,826 | |
| Taxation | 610 | 50.246% | 856 | 943 | 1,319 | (157,258) | |
| Profit / (Loss) from Discontinued Operations | (11,697) | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 3,171 | -33.200% | 12,063 | 53,708 | 45,259 | (447,481) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 18,230 | -- | (68,778) | (198,146) | (95,447) | 258,087 | |
| 2026/06 - Interim HKD(K$) | %Chg (Compare to Interim) | 2025/12 HKD(K$) | 2024/12 HKD(K$) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | |
| Net Finance Costs / (Income) | 26,766 | 113.701% | 19,465 | 16,458 | 1,569 | 3,342 |
| Depreciation & Amortisation | 16,854 | 130.340% | 16,440 | 21,416 | 55,580 | 66,401 |
| Directors' Emoluments | -- | -- | -- | 6,522 | 9,250 | 15,401 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Disclaimer | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 1.900 | -- | -7.000 | -20.500 | -9.900 | 26.800 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 1.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | 3.731% |
| Cash flow per share ($) | -- | -- | (0.047) | (0.157) | 0.199 | 0.501 |
| NBV per share ($) | 0.222 | -- | 0.196 | 0.272 | 0.480 | 0.626 |
| Remarks: | Real time quote last updated: 11/09/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K$) | HKD 18,230 |
| %Change | -- |
| EPS / (LPS) | HKD 0.019 |
| NBV Per Share ($) | HKD 0.222 |